What Is Selank?
Selank (TP-7) is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was developed by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences and the Zakusov State Research Institute of Pharmacology. Selank is structurally based on tuftsin (Thr-Lys-Pro-Arg), a naturally occurring immunomodulatory tetrapeptide derived from the Fc fragment of immunoglobulin G, with a proline-glycine-proline (Pro-Gly-Pro) sequence appended to extend its stability and modify its pharmacological profile.
Since its development in the late Soviet period, Selank has been registered in Russia as an anxiolytic and nootropic drug and has been the subject of numerous preclinical and clinical studies examining its effects on anxiety, cognition, immunity, and neurological function. It is typically administered intranasally, allowing direct access to the central nervous system via the olfactory pathway.
GABAergic Modulation and Anxiolytic Mechanism
The primary anxiolytic mechanism of Selank appears to involve potentiation of GABAergic neurotransmission, though via a mechanism distinct from classical benzodiazepines. Research has demonstrated that Selank enhances the effect of GABA at GABA-A receptors without directly binding to the benzodiazepine recognition site. This distinction is potentially significant because it suggests Selank may produce anxiolytic effects with a reduced risk of the tolerance, dependence, and withdrawal phenomena associated with benzodiazepine use.
Studies in rodent models using GABAergic antagonists have confirmed that blocking GABA-A receptors attenuates Selank’s anxiolytic effects, establishing a pharmacological dependency on this system. Additionally, research has implicated serotonergic and dopaminergic pathways in Selank’s action, with measurements showing modulation of serotonin metabolism in the frontal cortex and hippocampus following administration.
Selank also appears to inhibit the enzyme enkephalinase, which degrades endogenous enkephalins. Elevated enkephalin levels may contribute to anxiolytic effects through opioid receptor-mediated pathways, adding another dimension to this peptide’s multifactorial mechanism.
Anxiety Research in Animal Models
Selank has been studied in multiple validated rodent anxiety paradigms, including the elevated plus-maze, open field test, Vogel conflict test, and social interaction test. In these models, Selank consistently reduces anxiety-like behavior at doses typically in the microgram per kilogram range, with effects broadly comparable to classical anxiolytics such as diazepam and buspirone.
A key advantage observed in animal studies is the apparent absence of sedation at anxiolytic doses — a common limitation of benzodiazepines. Rodents treated with Selank maintained normal locomotor activity and exploratory behavior at doses that significantly reduced anxiety parameters, suggesting a more selective anxiolytic profile. This feature was a primary motivation for clinical development as an anxiolytic without sedative side effects.
Cognitive Enhancement Studies
Beyond anxiolytic effects, Selank research has explored cognitive enhancement properties. Studies have examined its effects on memory consolidation, learning speed, and attention in both normal animals and models of cognitive impairment. Selank administration in rodents has been associated with improved performance in spatial memory tasks and passive avoidance paradigms.
The cognitive-enhancing effects may relate to Selank’s ability to modulate brain-derived neurotrophic factor (BDNF) expression. Research has shown upregulation of BDNF in the hippocampus following Selank treatment, which is consistent with improved learning and memory consolidation, as BDNF is a critical mediator of synaptic plasticity and long-term potentiation.
Selank’s influence on the expression of genes related to neuroplasticity and stress response has also been demonstrated using transcriptomic approaches. Studies examining hippocampal gene expression found differential regulation of genes involved in synaptic transmission, oxidative stress protection, and immune modulation.
Russian Clinical Research Background
Selank has undergone formal clinical evaluation in Russia, culminating in its registration as a pharmaceutical drug for the treatment of generalized anxiety disorder and neurasthenia. Published clinical data, primarily from Russian institutions, describe studies in patients with anxiety disorders showing significant reductions in anxiety ratings on standardized scales (including the Hamilton Anxiety Rating Scale) with good tolerability.
Clinical observations have noted that Selank’s anxiolytic effects develop relatively rapidly (within days of initiation) without the withdrawal phenomena reported with benzodiazepines upon discontinuation. These clinical properties have attracted attention from researchers interested in developing anxiolytics with improved safety profiles.
Comparison to Benzodiazepines in Studies
Direct comparative studies between Selank and benzodiazepines in Russian clinical literature suggest broadly equivalent anxiolytic efficacy with a more favorable side effect profile. Key differences observed in research include the absence of significant muscle relaxation at therapeutic doses, no measurable impairment of psychomotor performance, and no observed physical dependence following discontinuation.
These comparative findings must be interpreted within the limitations of the available clinical literature, which largely consists of open-label and single-center trials rather than large multicenter randomized controlled studies. Independent replication by international research groups has been minimal, representing a significant gap in the evidence base for Selank’s clinical utility.
Memory Consolidation Research
A distinct area of Selank research focuses on its effects during and after stressful experiences — specifically whether it can preserve memory consolidation that stress typically impairs. Animal studies have demonstrated that Selank administration during conditioned stress paradigms can prevent the stress-induced deficit in long-term memory formation seen in control animals.
This finding is particularly relevant to conditions where anxiety and stress interfere with normal cognitive function, suggesting potential research applications in stress-related memory disorders and anxiety-associated cognitive impairment.
References
- Semenova TP, Kozlovskaya MM, Zakharova NM, Kozlovskii II. “Pharmacological characteristics of selective anxiolytic selank.” Eksperimental’naia i Klinicheskaia Farmakologiia. 2010;73(8):2–6.
- Konstantinopolsky MA, Fil’chenko AA, Lazareva NA, et al. “Selank modulates immunoreactive cells of tubulointerstitium of rat kidney in the streptozotocin-induced diabetes model.” Biochemical Pharmacology. 2012;83:606–613.
- Seredenin SB, Kozlovskaya MM, Bledov YA. “Anxiolytic effect of tuftsin analogue Selank in mice.” Eksperimental’naia i Klinicheskaia Farmakologiia. 1998;61(3):3–6.
- Volkova A, Shadrina M, Kolomin T, et al. “Analysis of gene expression in the hippocampus of anxious rats after administration of selank.” Journal of Molecular Neuroscience. 2016;59(2):209–217.
- Zolotarev YA, Dadayan AK, Bocharov EV, et al. “Biodegradation of selank in blood serum and pepsin-containing gastric juice.” Biochemistry (Moscow). 2006;71(9):1006–1012.